WHY IT MATTERS: Patients seeking medical cannabis products manufactured to pharmaceutical standards may find broader availability and greater product consistency if U.S. federal policy changes open legitimate pathways for GMP-certified producers to scale and export. CLINICAL OVERVIEW: Federal policy shifts around cannabis scheduling and executive action have historically created both opportunity and uncertainty for companies operating at the intersection of pharmaceutical-grade cannabis and international markets. When regulatory frameworks begin to clarify, manufacturers with established GMP infrastructure and clinical trial experience are better positioned to meet the evidentiary standards that pharmaceutical buyers and foreign health authorities require.